The 27-year follow-up is reported of 136 children whose mothers were involved in a randomised trial of high doses of stilboestrol and ethisterone therapy during pregnancy. The children were not contacted directly. Information about them was obtained from hospitals, general practitioners, and other official sources; and the persons who responded to our inquiries were unaware of who had been exposed to hormones in utero and whose mothers had received an inactive tablet. All children were traced. Urogenital anomalies were reported more frequently in the hormone-exposed than the unexposed children (14% and 9% respectively). The earlier in pregnancy the therapy began, the higher the prevalence rate of abnormalities (X2 for trend, p <0.02). No malignant tumours were reported.
SUMMARY
The 27-year follow-up is reported of 136 children whose mothers were involved in a randomised trial of high doses of stilboestrol and ethisterone therapy during pregnancy. The children were not contacted directly. Information about them was obtained from hospitals, general practitioners, and other official sources; and the persons who responded to our inquiries were unaware of who had been exposed to hormones in utero and whose mothers had received an inactive tablet. All children were traced. Urogenital anomalies were reported more frequently in the hormone-exposed than the unexposed children (14% and 9% respectively). The earlier in pregnancy the therapy began, the higher the prevalence rate of abnormalities (X2 for trend, p <0.02). No malignant tumours were reported.
For males, the proportion reported to be married or living as married was lower in the exposed than in the unexposed group (32% and 62% respectively). The proportion was lower the earlier in pregnancy hormonal exposure occurred and the higher the total hormone dose to which they were exposed (X2 for trend, p <0.02). These findings suggest that some interference with sexual function may not be uncommon in males exposed to high doses of stilboestrol and ethisterone while in utero.
During the 1940s encouraging reports suggested that the administration of oestrogens and progestogens during pregnancy could substantially reduce fetal loss rates.' Between 1940 and 1970, but mostly in the 1950s, an estimated 500 000 to 2 000 000 infants in the United States of America2 and 7800 in England and Wales3 had been exposed to exogenous sex hormones while in utero. In 1950 a randomised trial was set up in the United Kingdom to. evaluate the effects of high doses of stilboestrol and ethisterone on the outcome of pregnancy of diabetic mothers.4 The findings, which were consistent with those from other trials,5 6 revealed identical rates of spontaneous abortion (8%) and perinatal mortality (23%) in the hormone-treated and control groups. It For each child, the total dose to which it was exposed and the duration of pregnancy when therapy began was calculated. Where no additional information was recorded it was assumed that therapy began three days after the tablets were dispatched and concluded the day before childbirth. All durations of pregnancy reported here are measured as weeks since the last menstrual period (LMP). A duration of pregnancy of '7 weeks' refers to any time during the week beginning 7 weeks 0 days after the LMP and ending 7 weeks 6 days after the LMP. For calculating average durations of pregnancy, the number of days are taken into account as well.
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The follow-up procedure was identical to that described for the mothers.24 The children were not contacted directly, and all respondents to our inquiries were unaware whether the child was in the hormone-treated or non-hormone-treated group. We were notified of deaths, adoptions, and emigrations by the Office of Population Censuses and Surveys (OPCS). Copies of relevant death certificates were obtained. Post-mortem reports were available for the neonatal deaths, as part of the original study. For those who were still alive and had not been adopted or had not emigrated, a short questionnaire was sent to each subject's general practitioner (GP) asking about demographic factors and the occurrence of congenital or other abnormalities and tumours.
Results
At the time of entry into the trial the characteristics of the exposed and unexposed groups were comparable. Table 1 shows that the mean maternal ages and gravidities and the durations of pregnancy when therapy began were similar, as were the mean durations of pregnancy and birthweights.
All 136 births were traced by the OPCS. Two children had emigrated and three had been adopted (see Table 2 ). There were 18 stillbirths or deaths in Table 1 Characteristics of the hormone-exposed and unexposed children at the time of the original trial Hormones in utero the first year of life in each group. These had been reported previously.4 No obvious differences in the recorded causes of death were evident-the majority were ascribed to prematurity, atelectasis, or maternal diabetes. On the other hand there were differences in the types of abnormalities described at post-mortem examination, and these will be discussed later. Subsequently two deaths have occurred, both in females and both in the hormone-treated group. One died of asthma at 11 years of age, the other died in a motor vehicle accident at the age of 21. Of the remaining 93 children who, according to the OPCS, were alive, not adopted, and resident in the UK, completed questionnaires were obtained from their GPs for 85 (91%). Of the eight for whom no questionnaire was obtained, details of three could not be found on the files of their GP or area family practitioner committee; four were not currently registered with a GP (in all four cases the mother's GP informed us that the individual was alive); and in one case the GP was unwilling to complete our questionnaire.
There were 10 urogenital abnormalities in the 70 pregnancies exposed to hormones in utero and six in the 66 not exposed (14% and 9% respectively). Table  3 shows the types of urogenital abnormality in relation to the duration of pregnancy when the hormonal therapy began. The earlier the onset of therapy, the higher the proportion with abnormalities (X2 for trend = 5.9 p<0.02). The prevalence of other reported abnormalities was high, but no differences were evident between the exposed and unexposed groups. Overall, 14 (20%) of the exposed and 15 (23%) of the unexposed children had some abnormality recorded. Congenital heart 157 disease was noted in three of the exposed and four of the unexposed group; limb reduction defects in one exposed and one unexposed child; and a meningocoele in one unexposed child. Table 4 summarises the reported morbidity and other characteristics of the female offspring. The average age at follow-up was 27. Two benign but no malignant tumours were reported. Both were in the treated group. One girl had a fibroadenoma of the breast, another had multiple naevi on the face necessitating surgical removal. The numbers consulting their GPs with infections of the urogenital tract were similar in both groups. Two girls consulted their GPs with infertility and both were in the treated group. Both finally conceived, one requiring bromocriptene therapy. The proportions married were similar in both groups. The average number of children born to married women in the treated group was somewhat lower than in the untreated group but the difference is not statistically significant.
No malignant or benign tumours were reported in the males (Table 5 ). More hormone-exposed than unexposed males consulted their GPs with infections of the urogenital tract, but the numbers were small. The proportion of males reported by GPs as married or living as married was lower in the hormone-exposed than in the unexposed group (X2 = 3 0 p <0.1). Moreover, the proportion of males married or living as married was related to the duration of pregnancy when hormone therapy began (X2 for trend = 6-5 p <0.02) and to the dose of stilboestrol to which they were exposed (X2 for trend = 7.9 p <0.01) ( Table 6 ). The numbers were too small to disentangle whether the duration of pregnancy or the hormone dose was more strongly Also, some findings may be due to the fact that the mothers were diabetic. But neither of these factors could bias comparisons between the exposed and unexposed children. An important feature of this study is the massive doses of hormones to which the children were exposed. The dose of stilboestrol ranged from 8*4 g to 24-1 g, averaging 17 9 g. The range for ethisterone was 4-8 g to 23-0 g, averaging 15.3 g. In the Chicago study the children were exposed to 11 g of diethylstilboestrol and in other studies the diethylstilboestrol doses were considerably lower. 25 The duration of pregnancy when therapy was first administered ranged from seven to 20 weeks after the LMP, averaging 12.9 weeks for the exposed children and 13-1 weeks for the unexposed.
The high rate of urogenital abnormalities noted here in children and young adults exposed to stilboestrol and ethisterone in utero is consistent with the findings from other studies. Since we included every reported urogenital abnormality, both in deceased and living children, the severity varies considerably. Not all are necessarily congenital in Table 6 Percentage ofmales married or living as married by duration ofpregnancy when hormonal exposurefirst occurred and total dose ofstilboestrol to which they were exposed Hormones in utero origin, but as it is unclear where the division between congenital and non-congenital should be, all are presented here. The most interesting is the hermaphrodite in the treated group, as this condition is extremely rare. The child died five hours after birth and at post mortem was found to have an ovary on one side and an ovo-testis on the other. In addition, bilateral Kobelt's cysts and Mullerian cysts were described. In utero exposure to hormones began eight weeks after the mother's LMP. The male described in Table 3 as having underdeveloped external genitalia underwent special investigations as a child because of this but no obvious cause was found. In utero exposure to hormones began seven weeks after the mother's LMP. His GP reports that he is now 6 ft 1 inch tall, weighs more than 18 stone, but still has small external genitalia. Although we have not seen him, the description is reminiscent of another male in the Chicago study reported by Gill et all' as having 'bilateral hypotrophic testes . . . and eunuchoid body habitus'.
Of all those exposed to hormones in utero, the hermaphrodite and the male with underdeveloped external genitalia were among the four in whom exposure began particularly early in pregnancy. The third child died and was found to have double kidneys at post mortem; and the fourth has been adopted and so no follow-up information could be obtained. common in hormone-exposed than unexposed women.25 33 The subjects in Barnes's studies were not randomised, they knew whether or not they had been exposed to hormones; and the hormone doses to which they were exposed were relatively low. Information on marriage in males who were exposed to sex hormones in utero has not been reported previously, one reason being that the other studies were of younger men. The average age of the men in the Chicago study was 231011 whereas the average age in our study at the time of follow-up was 27. Our information on marriage and cohabitation was that reported by the subject's GP, who is often uncertain about the personal lives of male patients. Nevertheless it seems unlikely that the comparisons between exposed and unexposed groups would be biased because the GPs did not know whether the individuals were exposed to hormones or not. It is unlikely that the relationship with pregnancy duration and hormone dose is fortuitous. But our observations need to be confirmed elsewhere, ideally by obtaining information in a more direct manner. If they are valid, they suggest that some interference with sexual function may not be uncommon among males exposed in utero to high doses of stilboestrol and ethisterone. Such 
